Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating income | -$1.80M | -$5.86M |
| Net income | -$1.77M | -$3.19M |
| EPS (diluted) | -$0.07 | -$0.12 |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$1.36M | -$2.56M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Cash & equivalents | $498K | $4.03M |
| Total assets | $2.05M | $12.2M |
| Total liabilities | $2.23M | $7.48M |
| Shareholders' equity | -$177K | $4.69M |
| Retained earnings | -$19.2M | -$22.4M |
| Shares (wtd avg diluted) | 26.6M | 27.7M |
Every figure is extracted from Turn Therapeutics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.